**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 18712**

**Manuscript Type: TOPIC HIGHLIGHTS**

**2015 Advances in Liver Transplantation**

**Hemostasis in liver transplantation: pathophysiology, monitoring, and treatment**

HartmannM *et al*. Hemostasis in liver transplantation

Matthias Hartmann, Cynthia Szalai, Fuat H Saner

**Matthias Hartmann, Cynthia Szalai,** Klinik für Anaesthesiologie und Intensivmedizin, Universitätsklinikum Essen, Universität Duisburg-Essen, D-45122 Essen, Germany

**Fuat H Saner,** Klinik für Allgemeinchirurgie, Viszeral- und Transplantationschirurgie, Universitätsklinikum Essen, Universität Duisburg-Essen, D-45122 Essen, Germany

**Author contributions:** Hartmann M wrote the manuscript; Szalai C and Saner FH dicussed and corrected the manuscript.

**Conflict-of-interest statement:** Hartmann M and Saner FH have received honoria and funding for scientific lectures and retrospective data analyses from Szalai C Behring GmbH, Marburg. Szalai C declares no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**correspondence to: Matthias Hartmann, Professor,** Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Hufelandstr. 55, D-45122 Essen, Germany. matthias.hartmann@uni-due.de

**Telephone:** +49-201-7231402

**Fax:** +49-201-7235949

**Received:** April 27, 2015

**Peer-review started:** April 29, 2015

**First decision:** August 26, 2015

**Revised:** September 29, 2015

**Accepted:** November 13, 2015

**Article in press:**

**Published online:**

**Abstract**

Recent findings in the pathophysiology and monitoring of hemostasis in patients with end stage liver disease have major impact on coagulation management during liver transplantation. There is increasing evidence, that the changes in both coagulation factors and platelet count regularly observed in patients with liver cirrhosis cannot be interpreted as a reliable indicator of diffuse bleeding risk. Instead, a differentiated view on hemostasis has led to the concept of a rebalanced coagulation system: While it is important to recognize that procoagulant factors are reduced in liver cirrhosis, it is also evident that synthesis of anticoagulant factors and fibrinolytic proteins produced in the liver is also diminished. Similarly, the decreased platelet count may be counterbalanced by increased platelet aggregability caused by highly active von Willebrand multimeres. The coagulation system is therefor stated to be rebalanced. While under normal “unstressed” conditions diffuse bleeding is rarely observed, however both diffuse bleeding or thrombus formation may occur when compensation mechanisms are exhausted. While most patients presenting for liver transplantation have severe cirrhosis, liver function can be preserved in cholestatic liver disease and production of pro- and anticoagulant factors can be preserved. During liver transplantation, profound changes in the hemostasis system can occur. Surgical bleeding can lead to diffuse bleeding as coagulation factors and platelets are already reduced. Ischemia and tissue trauma can lead to alterations of hemostasis comparable to trauma induced coagulopathy. A further common disturbance often starting with the reperfusion of the transplanted organ hyperfibrinolysis which can eventually precipitate complete consumption of fibrinogen and an endogenous heparinization by glycocalyx shedding. Moreover, thrombotic events in liver transplantations are not uncommon and contribute to increased mortality. Besides conventional laboratory methods, bed-side monitoring of hemostasis (*e.g.*, thrombelastography, thrombelastometry) is often used during liver transplantation to rapidly diagnose decreases in fibrinogen and platelet count as well as hyperfibrinolysis and to guide treatment with blood products, factor concentrates, and antifibrinolytics. There is also evidence which suggests when algorithms based on bed-side hemostasis monitoring are used a reduction of blood loss, blood product use, and eventual mortality are possible. Notably, the bed-side monitoring of anticoagulant pathways and the thrombotic risk is not possible at time and thus a cautious and restrictive use of blood products is recommended.

**Key words:** Liver transplantation; Hemostasis; Bed-side monitoring; Thrombelastography; Thrombelastometry; Coagulation factors

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Hemostasis in patients presenting for liver transplantation is often characterized by a reduction in both pro- and anticoagulant factors. During surgery, the rebalanced hemostasis system can be stressed by bleeding, hemodynamic shock, tissue damage or substitution of blood products with resultant diffuse bleeding or thrombus formation. Thrombelastography/thrombelastometry can guide substitution of blood products and reduces bleeding, transfusion of blood products, and eventual mortality. It is, however, important to state that bed-side methods are not capable of detecting alterations in anticoagulant pathways. Thus cautious coagulation management is recommended to avoid potential devastating thrombotic complications.

Hartmann M, Szalai C, Saner FH. Hemostasis in liver transplantation: pathophysiology, monitoring, and treatment. *World J Gastroenterol* 2015; In press

**Coagulation system in liver disease**

Patients with end stage liver disease most often exhibit profound changes in hemostatic variables. An elevated international normalized ratio (INR) is common in cirrhosis and is used in conjunction with bilirubin and creatinine concentrations to determine the model of end-stage liver disease (MELD), which describes the severity of liver disease[1]. The liver synthesizes nearly all coagulation factors (FII, FV, FVII, FVIII, FIX, FX, FXI, FXII, FXIII) therefore, a reduction of factor activities can be regularly observed in end stage liver disease[2]. Von Willebrand factor, which plays an important role in hemostatic processes, is synthesized in endothelial cells and often exhibits increased activity is synthesized in endothelial cells and often exhibits increased activity in liver disease[3,4].

In addition, most inhibitors of coagulation (antithrombin, heparin cofactor II, protein C, protein S, and tissue factor pathway inhibitor), and components of the fibrinolytic sytem (plasminogen, α2-antiplasmin inhibitor, plasmin inhibitor) are synthesized in the liver and thus decreased levels are correspondingly observed in liver disease. In contrast, tissue type and urokinase-type plasminogen activator, and thrombomodulin are not synthesized by the liver and thus not affected by liver diseases[2].

Tissue factor produced by hepatocytes, is thought to contribute to the pathophysiology of liver diseases. Tissue factor is the principle physiological activator of coagulation. The fact, that hepatocytes express tissue factor and coagulation factors has been claimed as a “match in a dynamite factory” in a recent review[5]. In several models of liver injury, tissue factor deficiency was associated with reduced hepatic injury and inflammation. In accordance to the experimental findings, low molecular weight heparin reduced the frequency of hepatic decompensation in a prospective randomized study in 70 patients with cirrhosis[6]. Moreover, tissue factor showed a 38-fold increase in platelet poor plasma from patients with acute liver failure and was associated with mortality[7]. In another study, a 17-fold increase in circulating microparticle-bound tissue factor was observed in Child C patients[8]. For these reasons, increased tissue factor concentration may play a role in the hypercoagulable aspects of liver diseases. Some important mechanisms which may lead to hemostatic distubances in patients presenting for liver transplantation are given in Figure 1. Further details are given in the respective chapters of the review.

**Platelets in liver disease**

Platelet count is often decreased in advanced liver disease and several contributing mechanisms have been described. Hypersplenism represents the most important cause of thrombocytopenia followed by reduced platelet production due to the reduced synthesis of thrombopoietin, a hematopoietic growth factor, in the liver (for review see[9]). Further causative factors may include consumption of platelets due to coagulopathy and bone marrow suppression for examples in cases of Hepatitis C, or the use of antiviral or anticancer agents.

Similarly, platelets have been demonstrated to be involved in inflammatory processes in hepatitis B and preclinical data of antiplatelet therapy in liver disease suggest that inhibition of platelet function might be an effective mean to limit inflammation, fibrosis and even hepatocellular carcinoma development[10]. Importantly, platelet activity is often increased in liver disease as von Willebrand factor, derived from endothelium, is often elevated and the inactivating metalloproteinase ADAMTS13, synthesized in the liver, is often decreased[3,4].

**End stage liver disease and rebalanced hemostasis**

The above alterations in the hemostatic system were historically interpreted as indicators of bleeding risk in liver disease and patients were thought to be autoanticoagulated. There are many lines of evidence which contradict this point of view. Not only are procoagulant pathways reduced in liver disease but also fibrinolytic mechanisms are impaired. Moreover, low platelet count can be counterbalanced by increased platelet activity. Several clinical studies on the risk of bleeding and thrombosis suggest that liver disease is not simply a bleeding disorder but also confirm the concept of Lisman that the hemostatic system in liver disease is rebalanced[11].

The most common cause of bleeding in patients with liver disease is the rupture of esophageal varices. Every third patient with liver disease is affected by this life threatening complication[12]. Portal hypertension and local abnormalities of esophageal veins are significant contributing factors in the rupture while hemostasis is thought to be of minor importance at best[13].

A further argument against a general bleeding risk is the fact that nowadays liver transplantations can often be performed without requirement of blood product replacement, suggesting that the observed derangements in hemostatic variables might not translate to diffuse bleeding risk[14,15].

There are numerous reports on pulmonary embolism and cardiac thrombosis in liver transplantation. In a review of the 74 cases described in literature, symptoms most often included a decrease in arterial pressure, an increase in pulmonary arterial pressure and often complete circulatory collapse. Mortality rate was 68% with most deaths occurring already in the operation theatre[16].

Søgaard *et al*[17] demonstrated in a nationwide population-based case-control study, that liver disease is associated with a worsening risk for thromboembolism, the odds ratio was 2.1.

Liver biopsies and placement of intracranial pressure monitoring devices rarely led to bleeding complications[18,19].

**Hemostatic systems in patients presenting for liver transplantation vary with the underlying disease**

Many patients presenting for liver transplantation have end stage liver disease and thus present with reduced synthesis capacity and rebalanced hemostasis[11,20]. However, there is a minority of patients who are transplanted for other causes. Hemostasis system can be unaltered in patients presenting with hepatocellular carcinoma and intact liver function. Even hypercoagulability may be observed, particularly in cases of cholestatic liver disease and non-alcoholic fatty liver disease, due to inflammation, procoagulant shift of the endothelium, and the acute phase response.

**Dilution coagulopathy in liver transplantation**

Without doubt, surgical experience and technique has largely improved over time thus allowing liver transplantations to be performed in many cases without the need of transfusion. In certain situations (*e.g.*, retransplantation, previous intraabdominal surgery), however, massive surgical bleeding can still occur. The resultant dilution of coagulation factors and platelets may result in diffuse bleeding as the rebalanced hemostasis system is especially susceptible to further dilution of components. A combination of observed blood loss, platelet count and deterioration of both classical and bed-side hemostatic variables in conjunction with the onset of diffuse bleeding can easily lead to the appropriate diagnosis of a dilution coagulopathy.

**Trauma induced coagulopathy in liver transplantation?**

Recently, it has been recognized that trauma can induce a disturbance of hemostasis which cannot be explained by dilutional coagulopathy. Instead, tissue damage and hemodynamic shock are supposed to cause the so called trauma induced coagulopathy. Liver transplantation shares important characteristics with the pathophysiology of trauma induced coagulopathy, due to the huge surgical trauma and eventual hemodynamic disturbances caused by crossclamping of vena cava, cardiac decompensation, and massive bleeding.

Comparable alterations in molecular mechanisms of hemostasis can be observed in trauma and liver transplantation patients.

Derangements in the thrombin-thrombomodulin-protein C system leads to anticoagulation in trauma induced coagulopathy[21]. Accordingly, consumption of activated protein C in the liver was measured during transplantation. Activation and thus consumption of the protein C pathway, however, seems to be beneficial for the organism in trauma and liver transplantation, as a blockade of this system was detrimental in experimental shock and low protein C levels were associated with thrombosis in liver transplantation[22-24].

A further mechanism in both trauma and liver transplantation which leads to anticoagulation is the shedding of the anticoagulant glycocalyx from endothelium[25,26].

In trauma, a decrease in fibrinogen levels as well as hyperfibrinolysis are common events and are independent predictors of mortality[27,28]. Hyperfibrinolysis is also common in liver transplantation and associated with bleeding[29]. During the anhepatic phase, the clearance of tissue plasminogen activator is inhibited and additionally in the reperfusion phase accelerated release can occur from graft endothelium[30,31].

**Regional hypercoagulability in liver transplantations**

The pathophysiology of portopulmonary hypertension and hepatopulmonary syndrome are nowadays thought to be related to hemostasis. Hepatopulmonary syndrome is characterized by a ventilation perfusion mismatch observed in fifteen to twenty percent of patients presenting for liver transplantation and is associated with increased mortality[32]. Portopulmonary hypertension occurs in three to eight percent of patients and mortality is increased especially in severe cases[33,34]. It is thought that the procoagulant shift of the pulmonary endothelium might be central to the pathophysiology of both diseases[35]. Accordingly, intrapulmonary microthrombi have been demonstrated in an autopsy study in patients with portopulmonary hypertension. During liver transplantation, reperfusion of the organ can lead to an entrapment of platelets[36]. Sinusoidal obstruction syndrome, formely called veno-occlusive disease occurs after liver transplantation, the incidence was described to be 1.9% in a large series and is thought to be associated with acute rejection, endothelialitis, and extravasation of fibrinogen and platelets finally resulting in fibrosis[37-39]. Although only tested in patients after stem cell transplantation, defibrotide and tissue plasminogen activator are claimed to improve the prognosis.

**Monitoring of hemostasis during liver transplantation**

In patients presenting for liver surgery, hemostasis differs from patient to patient. Moreover, further alterations commonly occur during transplantation. Therefore, it seems plausible, that hemostasis monitoring might be beneficial. Plasma based laboratory tests and whole blood based bed-side monitoring are most commonly used.

Conventional tests for the monitoring of hemostasis often include INR, aPTT, fibrinogen values, and platelet count. Bed-side devices often used in liver transplantation are often thrombelastography (TEG, Haemonetics, Niles, Illinois, United States) and thrombelastometry (TEM; ROTEM, TEM Innovations, Munich, Germany). Several recent reviews on different aspects of the methods are available[31,40-42]. Both bed-side methods measure the viscoelastic properties of a clot in a time dependent manner. Differences between the devices are related to the number of channels, technical differences, and costs. Both devices allow to determine the time to onset of clot formation, the kinetics of clot formation, the firmness of a clot and eventual clot lysis. TEG allows to determine platelet function by the “platelet mapping test”, TEM allows the use of activators of the extrinsic and intrinsic system (called EXTEM, INTEM), as well as inhibitors of platelet aggregation (FIBTEM) and fibrinolysis (APTEM). A typical thrombelastogram obtained by TEM and the variables are given in figure 2. Characteristic changes due to hypofibrinogenemia, thrombocytopenia, hyperfibrinolysis, and heparin are shown in figure 3. In a new version, platelet function can also be determined by an impedance aggregometry module.

Activated partial thromboplastin time, INR, fibrinogen, and platelet count are correlated with TEM findings. However, the hemochron signature device (ITC, NJ, United States), which is capable to measure aPTT and INR in whole blood samples, demonstrated far better correlation with laboratory findings[43].

The advantages of laboratory based assay are the simplicity and reliability for the anesthetist, however a practical drawback includes the turnaround time of more than one hour. This implies, that result are often too late to guide immediate treatment of bleeding patients. In contrast, bed-side assays can be determined within a relative short time, often 10 to 30 min, as transportation and centrifugation of samples are not necessary. However, time and technical expertise for the measurements and interpretation of results by the anesthetist are still necessary.

**Which alterations in hemostasis can be detected by TEM**

Several alterations in hemostasis can be monitored by viscoelastic monitoring. Due to the fact, that our personal experiences are restricted to TEM, we limit our discussion to the typical findings with this device. Important changes It is important to state that both devices are used in liver transplantations.

Dilutional coagulopathy can easily be detected by the reductions in clot firmness in both tissue factor and sialic acid activated assays. In these assays the clot firmness is dependent on both fibrinogen concentration and platelet count. More specifically, contribution of platelets to clot firmness can be eliminated by cytochalasin D resulting in a thrombelastogram, the amplitude of which is then solely dependent on fibrinogen concentration (and eventual disturbances of fibrin polymerization).

TEM is ideal to detect hyperfibrinolysis. Normally, clot firmness only marginally decreases with time. In the case of hyperfibrinolysis, however, the clot is often completely degraded. The time to lysis can vary, in extreme cases the absence of clot formation can also be observed. Measurement in the presence of aprotinin abolishes clot lysis and confirms the diagnosis of hyperfibrinolysis.

Autoheparinization caused by shedding of the glycocalyx results in a prolongation of sialic acid activated clotting time. Diagnosis of heparin or glycocalyx mediated anticoagulation can be obtained by addition of heparinase.

Hypercoagulability can be diagnosed by increases in fibrinogen concentration and platelet count resulting in an increased clot firmness. Moreover, shortening of clotting time may be indicative for hypercoagulability.

TEM cannot detect alterations in procoagulant pathways, namely protein C, protein S, or antithrombin. Moreover, neither increased nor decreased platelet function can be distinguished (excetions are eventually platelet mapping and impedance aggregometry module, respectively).

**Does guidance by bed-side monitoring or conventional coagulation assays reduce bleeding and thrombosis?**

Concerning conventional coagulation assays, it is important to note that aPTT and INR were developed to monitor anticoagulation. Although often used as standard coagulation tests, there are no data to suggest that on the results of these, the risk of bleeding can be predicted or hemostasis therapy can be predicted or that treatment can be guided by these assays (for review see[44]). Conventional laboratory assays also failed to detect hypercoagulability[41]. Determination of thrombin-antithrombin-complexes, however, was predictive for portal vein thrombosis in patients with liver disease, but this method of monitoring is not readily available[45].

In contrast there is some evidence to indicate that viscoelastic methods can predict bleeding and thrombosis risk in patients presenting for liver transplantation. Potentially, whole blood viscoelastic methods containing both platelets and coagulation factors better simulate hemostasis alterations in vivo than highly artificial laboratory assays with platelet poor plasma. In a randomized controlled study, Wang *et al*[46] demonstrated that TEG in combination with a treatment algorithm reduced the transfusion of fresh frozen plasma but not 3-year survival in liver transplantation. Alamo *et al*[47] in a case-control study demonstrated that the use of TEM was associated with lower bleeding complications and mortality in high risk patients. Apart from liver transplantation, Wikkelsoe *et al*[40] concluded in their systemic review there is only weak evidence to support use of viscoelastic methods in patients at risk for massive bleeding. Intraoperative hypercoagulability was common in liver transplantation patient, especially in those presenting with cholestatic disease. Moreover thromboembolism was often associated with a hypercoagulable state as determined by viscoelastic methods[41].

**Viscoelastic monitoring to guide hemostasis interventions.**

Due to the complex alterations in hemostasis in liver transplantation, hemostasis treatment differs from patient to patient. Alterations in procoagulant pathways can best be detected by viscoelastic methods. However, there is no method to monitor all hemostasis alterations and anticoagulant pathways. Assuming a reduction of the procoagulant pathways is accompanied by comparable reductions in anticoagulant pathways, it seems logical (although not proven), that the thrombotic risk might be highest in those patients with the most pronounced decreases in procoagulant factors and platelet count. Therefore, in our opinion, it is of outmost importance to reduce procoagulant interventions in hemostasis in those patients, in which diffuse bleeding is apparent or can be expected from hemostasis findings. The need for transfusion can be guided by transfusion algorithms based on bed-side-viscoelastic methods[48]. In a Cochrane metaanalysis the authors came to the conclusion that use of viscoelastic methods might potentially decrease bleeding and transfusion demand in major surgery however further high quality studies were recommended[49].

**Prophylaxis and Treatment of coagulopathy in liver transplantation**

Evidence for the benefits of blood products is low in perioperative medicine, while the supporting evidence for side effects like negative transfusion effect, transfusion associated lung injury, transfusion associated circulatory overload, and infectious complications is increasingly acknowledged. Increased morbidity and mortality have been demonstrated to be associated with transfusion of blood products in liver surgery and liver transplantation (fresh frozen plasma, platelets, red blood cells)[50-53]. Besides improvements in surgical experience and techniques in liver transplantation, strategies to reduce the use of blood products termed patient blood management are increasingly used. For monitoring of hemostasis disturbances, TEG/ TEM are increasingly used and can guide the application of plasma component, platelets, and antifibrinolytics[54]. As bed-side-monitoring is increasingly used, the simple substitution of blood products by the 1:1:1 rule (red blood cells, fresh frozen plasma, platelets) is not encouraged in many liver transplantation centers.

***Prophylaxis of coagulopathy***

Concerning the use of a prophylactic intervention in hemostasis system, no benefit has been demonstrated so far so far for the use of fresh frozen plasma. Arguments against the use include the fact, that liver transplantation are nowadays increasingly done without blood products and fresh frozen plasma was associated with an increase in mortality in liver surgery[14,15,55]. In a multicenter randomized trial use of recombinant activated factor VIIa failed to reduce bleeding but increased arterial thrombotic events by 70%[56]. Controversity persists with respect to the importance of prophylactic antifibrinolytics in liver transplantation, both detrimental effect and no effect on blood transfusions have been described after withdrawal of aprotinin[57,58]. In a recent meta-analysis, the authors come to the conclusion, that aprotinin and tranexamic acid reduce transfusion requirements in patients undergoing liver transplantation and that there was no evidence that antifibrinolytic drugs increase thromboembolic events[59]. However, as TEG/TEM can detect hyperfibrinolysis, a prophylactic antifibrinolytic therapy seems not to be necessary nowadays. Some basic measures during surgery are of outstanding importance to prevent coagulopathy: body temperature has to be monitored and decreases can be prevented by forced air-warming devices and warming of intravenous fluids[60,61]. Also of relevance risk for coagulopathy increases with ischemic time and the transplantation of dysfunctional and marginal grafts[14,62].

***Fibrinogen in disturbances of hemostasis***

Fibrinogen is the first factor to reach critical levels when haemodilution or massive bleeding occurs[63]. Advantages of fibrinogen use in comparison with fresh frozen plasma are, the reduced rate of pathogen transmission as well as decreased risk of transfusion induced lung injury and transfusion induced circulatory overload. Fibrinogen concentration can easily be monitored by TEM and substitution therapy therapy based on guidance according to the clot firmness reduced the rate of red blood cells, fresh frozen plasma and platelet transfusion by more than 50%. Additionally the rate of transplantation without transfusion of the above blood related products rose from 3.5% to 20%[64]. In a recent review on fibrinogen and fresh frozen plasma in surgery and trauma, the authors concluded, that fibrinogen level was generally associated with improved outcome measures, while fresh frozen plasma failed to show evidence for effectivity and had severe side effects[65].

TEM-guided treatment with fibrinogen concentrate and/or prothrombin complex concentrate (PCC) did not appear to increase the occurrence of thrombosis, pulmonary and ischemic events compared to patients who did not receive these concentrates[15].

***Platelet transfusion***

Besides their proven and essential role in hemostasis, platelets are involved in innate immunity and inflammation. Platelet transfusion, in general, may lead to complications such as febrile non-hemolytic transfusion reactions, allergic reactions, transfusion-associated sepsis, and transfusion associated lung injury[66]. Furthermore, evidence from a multicenter observational studies with 504208 patients demonstrates that platelet transfusion was associated with venous and arterial thromboembolism as well as death in patients with cancer[67]. Prophylactic use of platelets in internal medicine should be restricted to a platelet count below 10000/µl[68].Higher values are recommended for surgical procedures, however, platelet count in patients presenting for liver transplantation are often above these limits. Thrombopoeitin receptor agonists may in the future be used to increase platelet count in liver disease, however, the possible risks and benefits are at present unknown[9].

In patients presenting for liver transplantation, platelet count is often reduced but platelet function is increased due to highly active von Willebrand multimeres[4]. Platelets are supposed to be entrapped after reperfusion of the liver, and an involvement in sinusoidal obstruction syndrome, portopulmonary hypertension, and hepatopulmonary syndrome has been suggested[32-39]. Transfusion of platelets was associated with increased mortality in liver transplantations[51]. Contribution of platelet count to clot firmness can be assessed by TEG/TEM. The originally methods are not sensitive for alterations in platelet function, however, platelet mapping and impedance aggregometry module, respectively, may extend the diagnostic capabilities. In a recent study, we demonstrated, that platelet function, determined with whole blood impedance aggregometry, was markedly increased in patients presenting for liver transplantation (manuscript in preparation). It might thus be conceivable, that bed-side platelet function testing during liver transplantation can provide further information on the use of platelet transfusions and the thromboembolic risk.

***Prothrombin complex concentrate***

Besides fibrinogen, other coagulation factors may decrease during liver transplantation resulting in a reduction of thrombin generation and prolongation of clotting time. In these cases, prothrombin complex concentrate can correct coagulopathy. In principle, there are four factor PCC and three factor PCC. Four factor PCC contain the factors II, VII, IX, and X, and the anticoagulant factors protein S and protein C[69]. Infectious risk is reduced or eliminated by virus elimination and thromboembolic complication occurs in only 0.9%. In liver transplantation, TEM guided substitution of blood products including prothrombin complex concentrate in liver transplantation did not increase the occurrence of thrombosis and ischemic events[15]. The safety and effectivity of prothrombin complex concentrate in liver transplantation is investigated in a prospective randomized study[70].

**Conclusion**

Alterations of hemostasis of patients presenting for liver transplantation are complex and can differ according to the underlying liver disease. In patients with end stage liver disease, standard laboratory findings like INR and platelet count suggest hypocoagulability. However, both pro- and anticoagulant pathways are often reduced resulting in a rebalanced system. Thus, both diffuse bleeding and thrombosis can occur during liver transplantation. The most common used methods for the timely diagnosis of hemostatic disturbances currently available are TEG/ TEM which with appropriate use can reduce the use of blood products. Substitution with coagulation factors, platelets, and fibrinolytics can be guided by algorithms if diffuse bleeding occurs (or can be supposed to occur by the results of measurements). At time, no bed-side method is capable to measure the alterations in anticoagulant pathways, thus cautious substitution of coagulation factors is recommended.

**References**

1 **Kamath PS**, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; **33**: 464-470 [PMID: 11172350]

2 **Wada H**, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. *Semin Thromb Hemost* 2008; **34**: 772-778 [PMID: 19214915]

3 **Hugenholtz GC**, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. *Hepatology* 2013; **58**: 752-761 [PMID: 23468040]

4 **Lisman T**, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. *Hepatology* 2006; **44**: 53-61 [PMID: 16799972]

5 **Kopec AK**, Luyendyk JP. Coagulation in liver toxicity and disease: role of hepatocyte tissue factor. *Thromb Res* 2014; **133** Suppl 1: S57-S59 [PMID: 24759146]

6 **Villa E**, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012; **143**: 1253-60.e1-4 [PMID: 22819864]

7 **Stravitz RT**, Bowling R, Bradford RL, Key NS, Glover S, Thacker LR, Gabriel DA. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. *Hepatology* 2013; **58**: 304-313 [PMID: 23389887]

8 **Rautou PE**, Vion AC, Luyendyk JP, Mackman N. Circulating microparticle tissue factor activity is increased in patients with cirrhosis. *Hepatology* 2014; **60**: 1793-1795 [PMID: 24470301]

9 **Hayashi H**, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. *World J Gastroenterol* 2014; **20**: 2595-2605 [PMID: 24627595]

10 **Aiolfi R**, Sitia G. Chronic hepatitis B: role of anti-platelet therapy in inflammation control. *Cell Mol Immunol* 2015; **12**: 264-268 [PMID: 25578311]

11 **Lisman T**, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. *Blood* 2010; **116**: 878-885 [PMID: 20400681]

12 **Sharara AI**, Rockey DC. Gastroesophageal variceal hemorrhage. *N Engl J Med* 2001; **345**: 669-681 [PMID: 11547722]

13 **Garcia-Tsao G**, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. *N Engl J Med* 2010; **362**: 823-832 [PMID: 20200386]

14 **Massicotte L**, Denault AY, Beaulieu D, Thibeault L, Hevesi Z, Nozza A, Lapointe R, Roy A. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. *Transplantation* 2012; **93**: 1276-1281 [PMID: 22617090]

15 **Kirchner C**, Dirkmann D, Treckmann JW, Paul A, Hartmann M, Saner FH, Görlinger K. Coagulation management with factor concentrates in liver transplantation: a single-center experience. *Transfusion* 2014; **54**: 2760-2768 [PMID: 24827116]

16 **Warnaar N**, Molenaar IQ, Colquhoun SD, Slooff MJ, Sherwani S, de Wolf AM, Porte RJ. Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review. *J Thromb Haemost* 2008; **6**: 297-302 [PMID: 18005235]

17 **Søgaard KK**, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. *Am J Gastroenterol* 2009; **104**: 96-101 [PMID: 19098856]

18 **Ewe K**. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. *Dig Dis Sci* 1981; **26**: 388-393 [PMID: 7249879]

19 **Karvellas CJ**, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM; U S Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. *Crit Care Med* 2014; **42**: 1157-1167 [PMID: 24351370]

20 **Northup PG**, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell SH; Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. *J Thromb Haemost* 2008; **6**: 2-9 [PMID: 17892532]

21 **Brohi K**, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. *J Trauma* 2008; **64**: 1211-127; discussion 1217 [PMID: 18469643]

22 **Chesebro BB**, Rahn P, Carles M, Esmon CT, Xu J, Brohi K, Frith D, Pittet JF, Cohen MJ. Increase in activated protein C mediates acute traumatic coagulopathy in mice. *Shock* 2009; **32**: 659-665 [PMID: 19333141]

23 **Kong HY**, Wen XH, Huang SQ, Zhu SM. Epsilon-aminocaproic acid improves postrecirculation hemodynamics by reducing intraliver activated protein C consumption in orthotopic liver transplantation. *World J Surg* 2014; **38**: 177-185 [PMID: 24142329]

24 **Akamatsu N**, Sugawara Y, Nakazawa A, Nishioka Y, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N. Hemostatic status in liver transplantation: association between preoperative procoagulants/anticoagulants and postoperative hemorrhaging/thrombosis. *Liver Transpl* 2015; **21**: 258-265 [PMID: 25370801]

25 **Ostrowski SR**, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. *J Trauma Acute Care Surg* 2012; **73**: 60-66 [PMID: 22743373]

26 **Schiefer J**, Lebherz-Eichinger D, Erdoes G, Berlakovich G, Bacher A, Krenn CG, Faybik P. Alterations of Endothelial Glycocalyx During Orthotopic Liver Transplantation in Patients With End-Stage Liver Disease. *Transplantation* 2015; **99**: 2118-2123 [PMID: 25757215]

27 **Rourke C**, Curry N, Khan S, Taylor R, Raza I, Davenport R, Stanworth S, Brohi K. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. *J Thromb Haemost* 2012; **10**: 1342-1351 [PMID: 22519961]

28 **Raza I**, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K. The incidence and magnitude of fibrinolytic activation in trauma patients. *J Thromb Haemost* 2013; **11**: 307-314 [PMID: 23176206]

29 **Roullet S**, Freyburger G, Labrouche S, Morisse E, Stecken L, Quinart A, Laurent C, Sztark F. Hyperfibrinolysis during liver transplantation is associated with bleeding. *Thromb Haemost* 2015; **113**: 1145-1148 [PMID: 25693891]

30 **Porte RJ**, Bontempo FA, Knot EA, Lewis JH, Kang YG, Starzl TE. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. *Transplantation* 1989; **47**: 978-984 [PMID: 2499962]

31 **Clevenger B**, Mallett SV. Transfusion and coagulation management in liver transplantation. *World J Gastroenterol* 2014; **20**: 6146-6158 [PMID: 24876736]

32 **Swanson KL**, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. *Hepatology* 2005; **41**: 1122-1129 [PMID: 15828054]

33 **Kawut SM**, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky HI. Hemodynamics and survival of patients with portopulmonary hypertension. *Liver Transpl* 2005; **11**: 1107-1111 [PMID: 16123953]

34 **Cartin-Ceba R**, Krowka MJ. Portopulmonary hypertension. *Clin Liver Dis* 2014; **18**: 421-438 [PMID: 24679504]

35 **Rodríguez-Roisin R**, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J* 2004; **24**: 861-880 [PMID: 15516683]

36 **Mende K**, Reifart J, Rosentreter D, Manukyan D, Mayr D, Krombach F, Rentsch M, Khandoga A. Targeting platelet migration in the postischemic liver by blocking protease-activated receptor 4. *Transplantation* 2014; **97**: 154-160 [PMID: 24434483]

37 **Nakanuma S**, Miyashita T, Hayashi H, Tajima H, Takamura H, Tsukada T, Okamoto K, Sakai S, Makino I, Kinoshita J, Nakamura K, Oyama K, Inokuchi M, Nakagawara H, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohta T. Extravasated platelet aggregation in liver zone 3 may correlate with the progression of sinusoidal obstruction syndrome following living donor liver transplantation: A case report. *Exp Ther Med* 2015; **9**: 1119-1124 [PMID: 25780397]

38 **Campos-Varela I**, Castells L, Dopazo C, Pérez-Lafuente M, Allende H, Len O, Llopart L, Vargas V, Charco R. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. *Liver Transpl* 2012; **18**: 201-205 [PMID: 21656652]

39 **Sebagh M**, Debette M, Samuel D, Emile JF, Falissard B, Cailliez V, Shouval D, Bismuth H, Reynès M. "Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. *Hepatology* 1999; **30**: 1144-1150 [PMID: 10534334]

40 **Wikkelsoe AJ**, Afshari A, Wetterslev J, Brok J, Moeller AM. Monitoring patients at risk of massive transfusion with Thrombelastography or Thromboelastometry: a systematic review. *Acta Anaesthesiol Scand* 2011; **55**: 1174-1189 [PMID: 22092122]

41 **Krzanicki D**, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. *Liver Transpl* 2013; **19**: 852-861 [PMID: 23696318 DOI: 10.1002/lt.23668]

42 **Tanaka KA**, Bader SO, Görlinger K. Novel approaches in management of perioperative coagulopathy. *Curr Opin Anaesthesiol* 2014; **27**: 72-80 [PMID: 24263685 DOI: 10.1097/ACO.0000000000000025]

43 **Herbstreit F**, Winter EM, Peters J, Hartmann M. Monitoring of haemostasis in liver transplantation: comparison of laboratory based and point of care tests. *Anaesthesia* 2010; **65**: 44-49 [PMID: 19889111 DOI: 10.1111/j.1365-2044.2009.06159.x]

44 **Haas T**, Fries D, Tanaka KA, Asmis L, Curry NS, Schöchl H. Usefulness of standard plasma coagulation tests in the management of perioperative coagulopathic bleeding: is there any evidence? *Br J Anaesth* 2015; **114**: 217-224 [PMID: 25204698 DOI: 10.1093/bja/aeu303]

45 Kalambokis GN, Oikonomou A, Baltayiannis G, Christou L, Kolaitis NI, Tsianos EV. Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis. *Hepatol Res* 2015; Epub ahead of print [PMID: 25847196 DOI: 10.1111/hepr.12520]

46 **Wang SC**, Shieh JF, Chang KY, Chu YC, Liu CS, Loong CC, Chan KH, Mandell S, Tsou MY. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. *Transplant Proc* 2010; **42**: 2590-2593 [PMID: 20832550 DOI: 10.1016/j.transproceed.2010.05.144]

47 **Alamo JM**, León A, Mellado P, Bernal C, Marín LM, Cepeda C, Suárez G, Serrano J, Padillo J, Gómez MÁ. Is "intra-operating room" thromboelastometry useful in liver transplantation? A case-control study in 303 patients. *Transplant Proc* 2013; **45**: 3637-3639 [PMID: 24314981 DOI: 10.1016/j.transproceed.2013.11.008]

48 **Görlinger K**. [Coagulation management during liver transplantation]. *Hamostaseologie* 2006; **26**: S64-S76 [PMID: 16953295]

49 **Gurusamy KS**, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. *Cochrane Database Syst Rev* 2011; **(12)**: CD009052 [PMID: 22161443 DOI: 10.1002/14651858.CD009052.pub2]

50 **de Boer MT**, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ, Porte RJ. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. *Anesth Analg* 2008; **106**: 32-44, table of contents [PMID: 18165548 DOI: 10.1213/01.ane.0000289638.26666.ed]

51 **Pereboom IT**, de Boer MT, Haagsma EB, Hendriks HG, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. *Anesth Analg* 2009; **108**: 1083-1091 [PMID: 19299765 DOI: 10.1213/ane.0b013e3181948a59]

52 **Tenza E**, Bernardo CG, Escudero D, Otero J, Quindós B, Miyar A, Vázquez L, Taboada F, Rodríguez M, González-Dìéguez L, González-Pinto I, Barneo L. Liver transplantation complications in the intensive care unit and at 6 months. *Transplant Proc* 2009; **41**: 1050-1053 [PMID: 19376424 DOI: 10.1016/j.transproceed.2009.02.014]

53 **Yildirim IO**, Salihoglu Z, Bolayirli MI, Colakoglu N, Yuceyar L. Prospective evaluation of the factors effective on morbidity and mortality of the patients having liver resection surgeries. *Hepatogastroenterology* 2012; **59**: 1928-1932 [PMID: 22369741]

54 **Tobin JM**, Tanaka KA, Smith CE. Factor concentrates in trauma. *Curr Opin Anaesthesiol* 2015; **28**: 217-226 [PMID: 25674987 DOI: 10.1097/ACO.0000000000000167]

55 **Weeder PD**, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. *Transfus Med Rev* 2014; **28**: 107-113 [PMID: 24721432 DOI: 10.1016/j.tmrv.2014.03.002]

56 **Planinsic RM**, van der Meer J, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardtsen E, Klintmalm G, Emre S. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. *Liver Transpl* 2005; **11**: 895-900 [PMID: 16035081 DOI: 10.1002/lt.20458]

57 **Schofield N**, Sugavanam A, Thompson K, Mallett SV. No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. *Liver Transpl* 2014; **20**: 584-590 [PMID: 24481770 DOI: 10.1002/lt.23839]

58 **Trzebicki J**, Kosieradzki M, Flakiewicz E, Kuzminska G, Wasiak D, Pacholczyk M, Lagiewska B, Lisik W, Kosson D, Kulik A, Chmura A, Lazowski T. Detrimental effect of aprotinin ban on amount of blood loss during liver transplantation: single-center experience. *Transplant Proc* 2011; **43**: 1725-1727 [PMID: 21693266 DOI: 10.1016/j.transproceed.2011.01.182]

59 **Molenaar IQ**, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. *Am J Transplant* 2007; **7**: 185-194 [PMID: 17227567 DOI: 10.1111/j.1600-6143.2006.01591.x]

60 **Bräuer A**, Quintel M. Forced-air warming: technology, physical background and practical aspects. *Curr Opin Anaesthesiol* 2009; **22**: 769-774 [PMID: 19734783 DOI: 10.1097/ACO.0b013e328331d134]

61 **Campbell G**, Alderson P, Smith AF, Warttig S. Warming of intravenous and irrigation fluids for preventing inadvertent perioperative hypothermia. *Cochrane Database Syst Rev* 2015; **4**: CD009891 [PMID: 25866139 DOI: 10.1002/14651858.cd009891.pub2]

62 **Broomhead RH**, Patel S, Fernando B, O'Beirne J, Mallett S. Resource implications of expanding the use of donation after circulatory determination of death in liver transplantation. *Liver Transpl* 2012; **18**: 771-778 [PMID: 22315207 DOI: 10.1002/lt.23406]

63 **Hiippala ST**, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. *Anesth Analg* 1995; **81**: 360-365 [PMID: 7542432]

64 **Noval-Padillo JA**, León-Justel A, Mellado-Miras P, Porras-Lopez F, Villegas-Duque D, Gomez-Bravo MA, Guerrero JM. Introduction of fibrinogen in the treatment of hemostatic disorders during orthotopic liver transplantation: implications in the use of allogenic blood. *Transplant Proc* 2010; **42**: 2973-2974 [PMID: 20970586 DOI: 10.1016/j.transproceed.2010.08.011]

65 **Kozek-Langenecker S**, Sørensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. *Crit Care* 2011; **15**: R239 [PMID: 21999308 DOI: 10.1186/cc10488]

66 **Refaai MA**, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. *Thromb Res* 2011; **127**: 287-291 [PMID: 21093892 DOI: 10.1016/j.thromres.2010.10.012]

67 **Khorana AA**, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch Intern Med* 2008; **168**: 2377-2381 [PMID: 19029504 DOI: 10.1001/archinte.168.21.2377]

68 **British Committee for Standards in Haematology, Blood Transfusion Task Force**. Guidelines for the use of platelet transfusions. *Br J Haematol* 2003; **122**: 10-23 [PMID: 12823341]

69 **Franchini M**, Lippi G. Prothrombin complex concentrates: an update. *Blood Transfus* 2010; **8**: 149-154 [PMID: 20671873]

70 **Arshad F**, Ickx B, van Beem RT, Polak W, Grüne F, Nevens F, Ilmakunnas M, Koivusalo AM, Isoniemi H, Strengers PF, Groen H, Hendriks HG, Lisman T, Pirenne J, Porte RJ. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. *BMC Surg* 2013; **13**: 22 [PMID: 23815798 DOI: 10.1186/1471-2482-13-22]

**P-Reviewer:** Marcos R, Kayaalp C **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

C:\Users\Administrator\Desktop\18712\Figure 1.tif

**Figure 1 Pathophysiology of hemostasis in patients presenting for liver transplantation.** A reduction in coagulation factors due to end stage liver disease worsens clot quality. Decreases in anticoagulant factors, fibrinolysis and ADAMTS 13 as well as increases in tissue factor and von Willebrand factor multimeres may favor disseminated intravascular coagulation (DIC). Shedding of glycocalyx induces a systemic anticoagulation and contributes to the procoagulatory shift of the endothelium. Note that pathophysiology may vary upon the underlying liver pathophysiology.

**C:\Users\Administrator\Desktop\18712\Figure 2.tif**

**Figure 2 Thrombelastometry variables most often used to interpretate a tracing.** The thrombelastogram shows the firmness of a clot during the measurement time. The clotting time is defined as the time from recalcification and activation of blood samples to the onset of coagulation. The maximum clot firmness describes the physical properties of a clot, which is defined by platelet count and fibrinogen concentration. The α angle and the clot formation time describe the kinetics of clot generation.

**C:\Users\Administrator\Desktop\18712\Figure 3.tif**

**Figure 3 Typical changes in thrombelastometry tracings.** Shown are the effects of hypofibrinogenemia, thrombocytopenia, hyperfibrinolysis, and heparin.